Ferroquine (FQ or SR97193) is a novel antimalarial drug candidate, currently in 
development at Sanofi-Aventis. In contrast to conventional drugs, FQ is the 
first organometallic drug: a ferrocenyl group covalently flanked by a 
4-aminoquinoline and a basic alkylamine. FQ is able to overcome the CQ 
resistance problem, an important limit to the control of Plasmodium falciparum, 
the principal causative agent of malaria. After fifteen years of effort, it is 
now possible to propose a multifactorial mechanism of action of FQ by its 
capacity to target lipids, to inhibit the formation of hemozoin and to generate 
reactive oxygen species.